The Companion Diagnostics (CDX) Market Forecast 2018-2028 - Visiongain Report
LONDON, April 19, 2018 /PRNewswire/ --
Leading Companies, Trends and Developments in the Growing Theranostics Market
Report Details
What can be expected from the Companion Diagnostics market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2028, assessing data, trends, opportunities and prospects there.
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
Our 183-page report provides 127 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole companion diagnostics market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2018-2028 and other analyses show you commercial prospects
Besides revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces
analysis) and commercial developments.
The report also includes will find revenue forecasts to 2028 for the following submarkets in the companion diagnostics market:
• Theranostics
• Other Companion Diagnostics
Additionally, this report includes a forecast to 2026 for the global in vitro diagnostics market.
The report also includes will find revenue forecasts to 2028 for the following national and regional markets for companion diagnostics:
• US
• Germany
• France
• Italy
• Spain
• UK
• Japan
• China
• India
• Russia
• Brazil
• South Korea
The report provides detailed profiles of key companies operating within the companion diagnostics market:
• F. Hoffmann-La Roche Ltd
• Qiagen N.V.
• Abbott Laboratories
• Agilent Technologies
• Myriad Genetics
• bioMerieux
• Thermo Fisher Scientific
Leading companies and potential for market growth
Overall revenue for the Companion Diagnostics market will reach $14.60n in 2023, our work forecasts. We predict strong revenue growth through to 2028. Advances in
cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will
drive sales to 2028.